⌘K

Login Start Free

Home/Filings/4/0000939767-21-000021

4//SEC Filing

Schwab Gisela 4

Accession 0000939767-21-000021

CIK 0000939767other

View on SEC.gov Company Profile

Filed

Feb 18, 7:00 PM ET

Accepted

Feb 19, 7:57 PM ET

Size

14.2 KB

Accession

0000939767-21-000021

Insider Transaction Report

Form 4

Period: 2021-02-17

EXELIXIS, INC.EXEL

EVP & Chief Medical Officer

Transactions

Exercise/Conversion
Common Stock
2021-02-17$1.70/sh+50,000$85,000→ 590,597 total
Sale
Common Stock
2021-02-17$22.50/sh−50,000$1,125,000→ 540,597 total
Exercise/Conversion
Common Stock
2021-02-18$1.70/sh+50,000$85,000→ 590,597 total
Sale
Common Stock
2021-02-18$22.35/sh−50,000$1,117,500→ 540,597 total
Exercise/Conversion
Option (right to buy)
2021-02-17−50,000→ 150,000 total
Exercise: $1.70From: 2015-07-20Exp: 2021-09-18→ Common Stock (50,000 underlying)
Exercise/Conversion
Option (right to buy)
2021-02-18−50,000→ 100,000 total
Exercise: $1.70From: 2015-07-20Exp: 2021-09-18→ Common Stock (50,000 underlying)

Holdings

Common Stock
(indirect: By 401(k))
14,880

Footnotes (3)

[F1]Includes 171,083 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
[F2]Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of February 17, 2021.
[F3]The option, representing the right to purchase a total of 500,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.

Documents

1 file

4
wf-form4_161378260922150.xmlPrimary
FORM 4

Issuer

EXELIXIS, INC.

CIK 0000939767

Entity typeother

Related Parties

1

filerCIK 0001213140

Filing Metadata

Form type: 4
Filed: Feb 18, 7:00 PM ET
Accepted: Feb 19, 7:57 PM ET
Size: 14.2 KB

View on SEC.gov